A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The researchers are doing this study to test the safety of combining bexarotene with TSEB
radiotherapy in people who have a common form of CTCL called mycosis fungoides (MF).
Bexarotene is a form of vitamin A that activates proteins called retinoid X receptors, which
may stop the growth of cancer cells and kill them. TSEB radiotherapy is a type of radiation
therapy that treats the entire surface of the skin with very low doses of radiation to kill
cancer cells and shrink tumors. This type of radiation does not pass through the outer layers
of the skin into the tissues and organs below the skin.
The study researchers think that giving bexarotene treatment at the same time as treatment
with TSEB radiotherapy may be more effective against MF than either treatment given alone or
in sequence (one after the other).